Managing the critical problems of advanced Parkinson’s disease

References

• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology56\(Suppl. 5), S1—S86 (2001).
   Google Scholar
• ••Extensive evidence-based review of allavailable therapies for PD.
   Google Scholar
• Agid Y, Olanow C, Mizuno Y. Levodopa: why the controversy? Lancet 360(9332), 575 (2002).
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58, 11–17 (2002).
   Google Scholar
• Rascol O, Goetz C, Koller Poewe Sampaio C. Treatment interventions for Parkinson's disease: an evidence-based assessment. Lancet 359, 1589–1598 (2002).
   PubMed Web of Science ®Google Scholar
• ••Extensive evidence-based review of allavailable therapies for PD.
   Google Scholar
• Korczyn AD, Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 62(5), 775–786 (2002).
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1, 345–349 (1977).
   PubMed Web of Science ®Google Scholar
• •Classic review of the issues associated with the long-term management of PD.
   Google Scholar
• Marsden CD. Parkinson's disease. j Neurol. Neurosurg. Psychiatry57, 672–681 (1994).
   PubMed Web of Science ®Google Scholar
• Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7, 117–124 (1992).
   Google Scholar
• Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 9, 2–12 (1994).
   PubMed Web of Science ®Google Scholar
• Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-Dopa in parkinsonian fluctuators. Neurology 36, 100–103 (1986).
   Google Scholar
• Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov. Disord 2, 73–91 (1987).
   Google Scholar
• Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1, 292–296 (1976).
   PubMed Web of Science ®Google Scholar
• Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov. Disord. 8, 257–262 (1993).
   PubMed Web of Science ®Google Scholar
• Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-Dopa: clinical and pharmacokinetic observations. Clin. Neuropharmacol. 9, 430–439 (1986).
   Google Scholar
• Pezzoli G, Tesei S, Ferrante C, Cossuna E, Zecchinelli A, Scarlato G. Madopar HBS in fluctuating parkinsonian patients: two-year treatment. Mov. Disord 3, 37–45 (1988).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K, van der Linden C. Comparison of Sinemet CR4 and standard Sinemet: double-blind and long-term open trial in parkinsonian patients with motor fluctuations. Mov. Disord 4, 303–309 (1989).
   Google Scholar
• Stocchi F, Bragoni M, Monge A et al. Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease: 6 months follow-up. N Trends Clin. Neuropharmacol. 12, 543–555 (1989).
   Google Scholar
• Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann. Neurol. 21, 370–376 (1987).
   Google Scholar
• Fabbrini G, Mouradian MM, Juncos J eta]. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann. Neurol. 24, 366–371 (1988).
   Google Scholar
• Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Wearing-off fluctuations in Parkinson's disease: central pathophysiology mechanisms, Part II. Ann. Neurol. 24, 372–378 (1988).
   PubMed Web of Science ®Google Scholar
• Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann. Neurol. 36, 27–31 (1994).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. j Neurol. Neurosurg. Psychiatry 57, 562–566 (1994).
   PubMed Web of Science ®Google Scholar
• Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease. Ann. Neurol. 25, 633–634 (1989).
   PubMed Web of Science ®Google Scholar
• Nutt JG. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 40, 340–345 (1990).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Schapira AHV, Rascol O. Continuous dopaminergic stimulation in the early treatment of PD. Trends NeUMSCI. 23, 117–126 (2000).
   Google Scholar
• Chase TN, Baronti F, Fabbrini G et al. Rationale for continous dopamimetic therapy of Parkinson's disease. Neurology 39, 7–10 (1989).
   PubMed Web of Science ®Google Scholar
• Baruzzi A, Contin M, Riva R et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin. Neuropharmacol. 10, 527–537 (1987).
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quingley EMM, Pfeiffer RE Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42, 726–732 (1992).
   PubMed Web of Science ®Google Scholar
• Valenzuela JE. Dopamine as a possible neurotransmitter in gastric relaxation. Castroenterology71, 1019–1022 (1976).
   PubMed Web of Science ®Google Scholar
• Leon AS, Speigel H. The effect of antacid administration on the absorption and metabolism of levodopa. Clin. Pharmacol. 12, 263–267 (1972).
   Google Scholar
• Kelly KA. Motility of the stomach and gastroduodenal junction. In: Physiology of the gastrointestinal tract. Johnson LR, (Ed.), Raven Press, New York, USA, 394–410 (1981).
   Google Scholar
• Sage JI, Trooskin S, Sonsalla PK, Heikkila RE, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann. Neurol. 24, 87–89 (1998).
   Google Scholar
• Kurlan R, Rubin AJ, Miller C et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: Preliminary observations. Ann. Neurol. 20, 262–265 (1986).
   PubMed Web of Science ®Google Scholar
• Syed N, Murphy J, Zimmerman T, Mark MH, Sage N. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov. Disord. 13, 336–338 (1998).
   Google Scholar
• •Long-term review of the benefits of L-dopa infusion.
   Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP et al. The 'on-off' phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl. J. Med. 310,483–488 (1984).
   PubMed Web of Science ®Google Scholar
• Leenders Kl, Poewe WH, Palmer AJ et al. Inhibition of L-(19F)-fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann. Neurol. 20,258-262 (1986).
   Google Scholar
• Kurth MC, Tetrud JW, Tanner CM et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43, 1698–1703 (1993).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Ruggieri S, Monge A et al. Clinical efficacy of single morning doses of different levodopa formulations. Clin. Neuropharmacol. 17\(Suppl. 3), S16—S20 (1994).
   Google Scholar
• Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L, Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J. Neurol. 243(5), 377–380 (1996).
   PubMed Web of Science ®Google Scholar
• Steiger MJ, Stocchi F, Bramante L, Ruggieri S, Quinn NE The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson's disease. Clin. Neuropharmacol. 15(6), 501–504 (1992).
   PubMed Web of Science ®Google Scholar
• Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55\(Suppl. 1), 23–30 (1998).
   Google Scholar
• The Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol 42,747–755. (1997).
   PubMed Web of Science ®Google Scholar
• Poewe W, Deuschl G, Gordin A and Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-months randomized placebo-controlled double-blind study in Germany and Austria. Acta Neurol. Scand. 105(4), 245–255 (2002).
   Google Scholar
• Larsen JP, Siden A, Worm-Peterson J et al. Long-term efficacy and safety of entacapone in Parkinsonian patients with motor fluctuations: a Nordic open study of
   Google Scholar
• years duration. Poster presented at the 14th International Congress on Parkinson's disease (ICPD), Helsinki, Finland. July 27—August 1 (2001).
   Google Scholar
• Sagar H, Brooks D, UK-Irish Entacapone Study Group. The UK-Irish double-blind study of entacapone in Parkinson's disease. Mov. Disord 15 (Suppl. 3), 135 (2000).
   Google Scholar
• Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur. Neurol 45,111–118 (2001).
   Google Scholar
• Adler CH, Singer C, O'Brien C et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol 55,1089–1095 (1998).
   Google Scholar
• Troconiz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin. Pharmacol. Ther 64,106–116 (1998).
   PubMed Web of Science ®Google Scholar
• Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin. Pharmacokinet. 40,383–393 (2001).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Beckner RM et al. Effect of peripheral catechol-0-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44, 913–919 (1994).
   PubMed Web of Science ®Google Scholar
• Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology44,77–80 (1994).
   Google Scholar
• Olanow CW and the Tasmar advisory panel. Tolacapone and hepatotoxic effects. Arch. Neurol 57,263–267 (2000).
   PubMed Web of Science ®Google Scholar
• Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR, Rubbici-Brandt L. Tolcapone and fulminant hepatitis. Lancet 352,958 (1998).
   Google Scholar
• Blum MW, Siegel AM, Meier R, Hess K. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication. Eur. Neurol 46, 158–160 (2001).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for early use of COMT inhibitors. Neurology Suppl. 4), S72-77 (2000).
   Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, DeDeyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
   Google Scholar
• Study Group. N Engl. J Med 342, 1481–1491 (2000).
   Google Scholar
• •Long-term dopamine agonist study showing delaying of motor complications.
   Google Scholar
• Parkinson's Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's disease. JAMA 284,231-238 (2000).
   Google Scholar
• Langtry HD, Clissold SE Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 39,491–506 (1990).
   PubMed Web of Science ®Google Scholar
• Rabey JM, Streifler M, Treves T, Korczyn AD. A long-term comparative study of lisuride and levodopa in Parkinson's disease. In: Parkinsonism and aging. Calne DB, Comi G, Crippa D etal. (Eds). Raven Press, New York, USA, 261–267 (1989).
   Google Scholar
• Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 43, 613–616 (1993).
   Google Scholar
• Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD. Beneficial effect of cabergoline, new long-lasting D-2 agonist in the treatment of Parkinson's disease. Clin. Neuropharmacol. 17,286-293 (1994).
   Google Scholar
• Rinne UK, Bracco F, Chousa C eta]. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 48, 363–368 (1997).
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Brooks DJ, Brunt ER eta]. Ropinirole versusbromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 13,46–51 (1998).
   Google Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment in the treatment of early Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology49,1060–1065 (1997).
   Google Scholar
• Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology45, S13–21 (1995).
   Google Scholar
• Pezzoli G, Martignoni E, Pacchetti C et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov. Disord 9,431–436 (1994).
   PubMed Web of Science ®Google Scholar
• Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1(8123), 954–956 (1979).
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. j Neurol. Neurosurg. Psychiatry53, 96–101 (1990).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov. Disord 8,165–170 (1993).
   PubMed Web of Science ®Google Scholar
• Attanasio A, Capria C, Leggiardro G et al. Transient cardiac arrest during continuous iv. infusion of apomorphine. Lancet 336(8726), 1321 (1990).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesia. Ann. Neurol 47,167–178 (2000).
   Web of Science ®Google Scholar
• •Review of the concepts of continuous dopaminergic stimulation in avoiding the development of motor complications.
   Google Scholar
• Obeso JA, Rodriguez-Oroz MC, Rodriguez M et al. Pathophysiology of the basal ganglia in PD. Trends Neurosci. 23,8–19 (2000).
   PubMed Web of Science ®Google Scholar
• Calon F, Grondin R, Morissette M et al. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol 47,70–78 (1998).
   Web of Science ®Google Scholar
• Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547,152–161 (1991).
   Google Scholar
• Bédard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-dopa but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 379,294-299 (1986).
   Google Scholar
• Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropiniroleand bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord 13,234–241 (1998).
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Calon F, Martel JC et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. j Pharmacol. Exp. Ther: 272, 854–859 (1995).
   Google Scholar
• Morissette M, Goulet M, Soghomonian JJ etal. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Md. Brain Res 49,55–62 (1997).
   Google Scholar
• Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125,2058–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 34 patients. Brain 114, 601–614 (1991).
   Google Scholar
• Stocchi F, Bramante L, Monge A et al. Apomorphine and lisuride infusion: A comparative study. Adv. Neurol 60,653–655 (1993).
   PubMedGoogle Scholar
• Colzi A, Turner K, Lees AJ. Continuous sc. waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesia in Parkinson's disease. j Neurol. Neurosurg. Psychiatry 64,573–576 (1998).
   Google Scholar
• Stibe CMN, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1(8582), 403–406 (1988).
   PubMed Web of Science ®Google Scholar
• Nilsson D, Hannsson L, Johansson K, Nystrom C, Paalzow LK, Aquilonius S. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol. Scand. 97,175–183 (1998).
   PubMed Web of Science ®Google Scholar
• Pietz K, Hagell P, Odin P Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow-up. J. Neurol. Neurosurg. Psychiatry 65,709–716 (1998).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Farina C, Nordera GP, Ruggieri S. Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. Mov. Disord 14,358 (1999).
   PubMed Web of Science ®Google Scholar
• Spiegel E, Wycis H, Baird H. Long-range effects of electropallidodensotomy in extrapyramidal and convulsive disorders. Neurology8, 734–740 (1958).
   Google Scholar
• Hallett M, Litvan I. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's disease. Neurology53,1910–1921 (1999).
   Google Scholar
• •Review of deep-brain surgery for advanced PD.
   Google Scholar
• Parent A, Hazrati LN. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Brain Res. Rev 20,128–154 (1995).
   PubMed Web of Science ®Google Scholar
• Diederich N, Goetz CG, Stebbins GT et al. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology42, 1311–1314 (1992).
   PubMed Web of Science ®Google Scholar
• Fox MW, Ahlskog JE, Kelly, PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients. j Neurosurg. 75,723–730 (1991).
   PubMed Web of Science ®Google Scholar
• Guridi J, Herrero MT, Luquin R, Guillen J, Obeso JA. Subthalamotomy improves MPTP-induced parkinsonism in monkeys. Stereotact. Funct. Neurosurg. 62,98–102 (1994).
   PubMedGoogle Scholar
• Giller CA, Dewey RB, Ginsburg MI, Mendelsohn DB, Berk AM. Stereotactic pallidotomy and thalamotomy using individual variations of anatomic landmarks for localization. Neurosurgery42, 56–62 (1998).
   Google Scholar
• Benabid AL, Pollak, P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nuceus for bilateral Parkinson's disease. Appl. Neurophysiol 50, 344–346 (1987).
   Google Scholar
• Benabid AL, Pollak, P, Gao D et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J. Neurosurg. 84,203–214 (1996).
   PubMed Web of Science ®Google Scholar
• Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P Long-term electrical inhibition of deep brain targets in movement disorders. Mov. Disord 13\(Suppl. 3), 119–125 (1998).
   Google Scholar
• Krack P, Pollak P, Limousin P et al. Subthalamic nucleus or internal pallidal stimulation in young-onset Parkinson's disease. Brain 121, 451–457 (1998).
   PubMed Web of Science ®Google Scholar
• Kumar R, Lozano AM, Kim YJ et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51 850–855 (1998).
   PubMed Web of Science ®Google Scholar
• Bejjani BP, Arnulf I, Demeret S et al. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann. Neurol 47, 655–658 (2000).
   Web of Science ®Google Scholar
• Lindvall O, Bjorklund A. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials. Acta NeuroL Scand Suppl. 126, 197–210 (1989).
   PubMedGoogle Scholar
• Lindvall O, Sawle G, Widner H et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. NeuroL 35, 172–180 (1994).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19, 102–109 (1996).
   PubMed Web of Science ®Google Scholar
• Lindvall O, Brundin P, Widner H et al. Grafts of fetal dopamine neurones survive and improve motor function in Parkinson's disease. Science 247, 574–577 (1990).
   PubMed Web of Science ®Google Scholar
• Freed CR, Breeze RE, Rosenberg NL et al. Survival of implanted dopamine cells and neurologic improvement 12 to 16 months after transplantation for Parkinson's disease. N EngL Med. 327, 1549–1555 (1992).
   PubMed Web of Science ®Google Scholar
• Peschanski M, Defer G, N'Guyen JP eta]. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117, 487–499 (1994).
   Google Scholar
• Clarkson ED. Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results. Drugs Aging18(10), 773–785 (2001).
   PubMed Web of Science ®Google Scholar
• Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP). N Eng/. Med. 327, 1556–1563 (1992).
   Google Scholar
• Kordower JH, Freeman TB, Snow BJ et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. NEngl.J. Med. 332, 118–124 (1995).
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl. j Med. 344(10), 710–719 (2001).
   Google Scholar
• Hauser RA, Freeman TB, Snow BJ eta]. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch. Neurol 56, 179–187 (1999).
   Google Scholar
• Lindvall O. Neural transplantation in Parkinson's disease. In: Functional neural transplantation. Dunnett SB, Bjorklund A, (Eds). Raven Press, New York, USA, 103–137 (1994).
   Google Scholar
• Deacon T, Schumacher J, Dinsmore J eta]. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. 3(3), 350–353 (1997).
   Google Scholar
• Aebischer P, Goddard M, Signore AP, Timpson Rl. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. Exp. Neurol 126, 151–158 (1994).
   Google Scholar
• Date I, Shingo T, Yoshida H, Fujiwara K, Kobayashi K, Ohmoto T. Grafting of encapsulated dopamine-secreting cells in Parkinson's disease: long-term primate study. Cell Transplant 9(5), 705–709 (2000).
   PubMed Web of Science ®Google Scholar
• McRae UJ, Dahlstrom A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striate of rats with 6-0H-DA induced parkinsonism. Neurochem. Int. 25, 27–33 (1994).
   Google Scholar
• Kang UJ, Fisher LJ, Joh TH, O'Malley KU, Gage FH. Regulation of dopamine production by genetically modified primary fibroblasts. Neurosci. 13, 5203–5211 (1993).
   Google Scholar
• During MJ, Naegele JR, O'Malley KU, Geller Al. Long-term behavioural recovery in parkinsonian rates by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399–1403 (1994).
   Google Scholar
• Tornatore C, Baker-Cairns B, Yadid G et al Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum. Cell Transplant. 5(2), 145–163 (1996).
   Google Scholar
• Corti O, Sanchez-Capelo A, Cohn P, Hanoun N, Hamon M, Mallet J. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direst adenovirus-mediated gene transfer to a rate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 96(21), 12120–12125 (1999).
   Google Scholar
• Hoffer BJ, Hoffman A, Bowenkamp eta]. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurones in vivo. Neurosci. Lett. 182, 107–111 (1994).
   Google Scholar
• Zurn AD, Widmer HR, Aebischer P. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. Brain Res. Brain Res. Rev 36(2–3), 222–229 (2001).
   Google Scholar
• Huber SJ, Paulson GW Management of behavioural symptoms in Parkinson's disease. In: Therapy of Parkinsoth disease. Koller WC (Ed.), Marcel Dekker, New York, USA, 557–566 (1990).
   Google Scholar
• Rabey JM, Treves TA, Neufeld MY, Orlow E, Korczyn AD. Low dose clozapine in the treatment of levodopa-induced mental distrubances in Parkinson's disease. Neurology 45, 432–434 (1995).
   Google Scholar
• Lees AJ. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. Eur. Neurol 27\(Suppl. 1), 126–134 (1987).
   Google Scholar
• Laihnen A, Alihanka J, Raitasuo et al. Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease. Acta NeuroL Scand. 76, 64–68 (1987).
   PubMed Web of Science ®Google Scholar
• Baas HK, Schueler P Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur. Neurol 46\(Suppl. 1), 18–23 (2001).
   Google Scholar
• Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol 56(11), 1383–1386 (1999).
   Google Scholar
• Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov. Disord 17 (Suppl. 4), S13-22 (2002) .
   Google Scholar
• Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 39, 1219–1221 (1989).
   PubMed Web of Science ®Google Scholar
• Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 41,1699–1700 (1991).
   Google Scholar
• Brandstadter D, Oertel WH. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 58 (1), 156–162 (2002).
   Web of Science ®Google Scholar
• Ruggieri S, De Pandis ME Bonamartini A, Vacca L, Stocchi E Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin. Neuropharmacoi 20(3), 204–209 (1997).
   PubMed Web of Science ®Google Scholar
• Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov. 17(4), 676–681 (2002).
   Google Scholar
• Fitzmaurice H, Fowler CJ, Richards D et al. Micturation disturbances in Parkinson's disease. Br. J. Urol. 57,652–656 (1985).
   PubMedGoogle Scholar
• Eichhom TE, Oertel WH. Macrogol 3350/ electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disorcl. 16(6), 1176–1177 (2001).
   Google Scholar
• Merello M, Leiguarda R. Adynamic bowel syndrome in Parkinson's disease with dramatic response to apomorphine. Ann. Neurol. 33,490–493 (1993).
   PubMed Web of Science ®Google Scholar